{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:17:49Z","timestamp":1793783869159,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA007233"],"award-info":[{"award-number":["T32DA007233"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["5P30 DA01104123"],"award-info":[{"award-number":["5P30 DA01104123"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Racial and Ethnic Health Disparities"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stigma surrounding opioid use disorder (OUD) and medications for opioid use disorder (MOUD), such as methadone, remains a significant barrier to care, despite the effectiveness of MOUD. Intersectional stigma tied to addiction, methadone treatment, structural racism, and classism disproportionately affects minoritized people with OUD, with direct consequences for health and wellbeing. Less is known about how Black and Latine people in methadone treatment think about and experience various dimensions of stigma related to addiction and the social determinants of health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Semi-structured interviews were conducted with Black and Latine patients from two Newark, NJ, United States, methadone clinics (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200937). Participant experiences and perceptions around SUD, MOUD, and stigma were explored. Participant transcripts were thematically coded to identify recurring themes and perspectives.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three major themes emerged: First, participants rejected views of addiction as a choice or moral failing, instead framing addiction as a chronic disease shaped by environment, trauma, and social pressure. Second, participants framed methadone as a legitimate, recovery-facilitating medical treatment, directly challenging the stigma that reduces it to a mere substitute. Third, participants emphasized that intersectional stigma related to substance use, structural racism, and classism significantly harmed their care, particularly noting resource deficits that disproportionately neglect Black and Latine communities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Reducing structural stigma is critical to improving access to MOUD for populations affected by structural inequity. Institutional efforts to reduce stigma and expand low-threshold programs are critical to expanding MOUD access and uptake. Intentional efforts to build trust with minoritized populations are essential to advance equity and can be achieved by acknowledging and addressing the structural drivers that shape people\u2019s daily lived experiences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40615-026-03074-z","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:42:10Z","timestamp":1783089730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cIn My Community, if You\u2019re an Addict, People Don\u2019t Just Look Down on You for the Drugs, but for Being Black, Too\u201d: Black and Latine Methadone Patients\u2019 Experiences Around Addiction, Methadone Treatment, and Intersectional Stigma"],"prefix":"10.1007","author":[{"given":"A. M.","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Katundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Alnashri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Grin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"2","key":"3074_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10826084.2017.1363238","volume":"53","author":"SE Wakeman","year":"2018","unstructured":"Wakeman SE, Rich JD. Barriers to Medications for Addiction Treatment: How Stigma Kills. Subst Use Misuse. 2018;53(2):330\u20133.","journal-title":"Subst Use Misuse"},{"issue":"11","key":"3074_CR2","doi-asserted-by":"publisher","first-page":"e1002969","DOI":"10.1371\/journal.pmed.1002969","volume":"16","author":"AC Tsai","year":"2019","unstructured":"Tsai AC, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019;16(11):e1002969.","journal-title":"PLoS Med"},{"issue":"3","key":"3074_CR3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1057\/s41296-021-00490-0","volume":"20","author":"PH Collins","year":"2021","unstructured":"Collins PH, et al. Intersectionality as Critical Social Theory. Contemp Political Theory. 2021;20(3):690\u2013725.","journal-title":"Contemp Political Theory"},{"key":"3074_CR4","doi-asserted-by":"crossref","unstructured":"Crenshaw* K. Mapping the margins: Intersectionality, identity politics, and violence against women of color. Stanford Law Review; 1991. pp. 1241\u20131299.","DOI":"10.2307\/1229039"},{"issue":"5","key":"3074_CR5","first-page":"466","volume":"113","author":"M Kirsty","year":"2022","unstructured":"Kirsty M, Sievwright M, Stangl AL, PhD MPH, Laura Nyblade PD. An Expanded Definition of Intersectional Stigma for Public Health Research and Praxis. Am J Public Health. 2022;113(5):466\u201374.","journal-title":"Am J Public Health"},{"issue":"3","key":"3074_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1037\/sah0000426","volume":"8","author":"SM Walters","year":"2023","unstructured":"Walters SM, et al. Intersectional Stigma as a Fundamental Cause of Health Disparities: A case study of how drug use stigma intersecting with racism and xenophobia creates health inequities for Black and Hispanic persons who use drugs over time. Stigma Health. 2023;8(3):325\u201343.","journal-title":"Stigma Health"},{"key":"3074_CR7","doi-asserted-by":"crossref","unstructured":"Davis S et al. Substance use stigma and community drug checking: A qualitative study examining barriers and possible responses. Int J Environ Res Public Health. 2022;19(23).","DOI":"10.3390\/ijerph192315978"},{"issue":"4","key":"3074_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s11013-016-9496-5","volume":"40","author":"J Netherland","year":"2016","unstructured":"Netherland J, Hansen HB. The War on Drugs That Wasn\u2019t: Wasted Whiteness, Dirty Doctors, and Race in Media Coverage of Prescription Opioid Misuse. Cult Med Psychiatry. 2016;40(4):664\u201386.","journal-title":"Cult Med Psychiatry"},{"key":"3074_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.drugpo.2017.05.050","volume":"46","author":"L Beletsky","year":"2017","unstructured":"Beletsky L, Davis CS. Today\u2019s fentanyl crisis: Prohibition\u2019s Iron Law, revisited. Int J Drug Policy. 2017;46:156\u20139.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"3074_CR10","first-page":"115","volume":"53","author":"M Alexander","year":"2011","unstructured":"Alexander M. The New Jim Crow: mass incarceration in the age of colorblindness. Inst Race Relations. 2011;53(1):115\u201325.","journal-title":"Inst Race Relations"},{"key":"3074_CR11","doi-asserted-by":"crossref","unstructured":"Tyndall M. The North American overdose crisis: How structural violence, prohibition and stigma have paralyzed our response. Sexual health at the intersection of substance use and social inequality; 2019.","DOI":"10.1136\/sextrans-2019-sti.40"},{"issue":"14","key":"3074_CR12","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, et al. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review. Subst Use Misuse. 2021;56(14):2181\u2013201.","journal-title":"Subst Use Misuse"},{"issue":"5335","key":"3074_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1126\/science.278.5335.45","volume":"278","author":"AI Leshner","year":"1997","unstructured":"Leshner AI. Addiction is a brain disease, and it matters. Science. 1997;278(5335):45\u20137.","journal-title":"Science"},{"issue":"2","key":"3074_CR14","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3(2):e1920622.","journal-title":"JAMA Netw Open"},{"key":"3074_CR15","doi-asserted-by":"publisher","first-page":"114992","DOI":"10.1016\/j.socscimed.2022.114992","volume":"302","author":"P Mitchell","year":"2022","unstructured":"Mitchell P, et al. Geographic disparities in access to Medication for Opioid Use Disorder across US census tracts based on treatment utilization behavior. Soc Sci Med. 2022;302:114992.","journal-title":"Soc Sci Med"},{"issue":"2","key":"3074_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/00220426231204841","volume":"55","author":"M Hutchison","year":"2023","unstructured":"Hutchison M, et al. Trends and Barriers of Medication Treatment for Opioid Use Disorders: A Systematic Review and Meta-Analysis. J Drug Issues. 2023;55(2):193\u2013214.","journal-title":"J Drug Issues"},{"key":"3074_CR17","first-page":"117822182211038","volume":"16","author":"J Dickson-Gomez","year":"2022","unstructured":"Dickson-Gomez J, et al. You\u2019re Not Supposed to be on it Forever: Medications to Treat Opioid Use Disorder (MOUD) Related Stigma Among Drug Treatment Providers and People who Use Opioids. Subst Abuse. 2022;16:11782218221103859.","journal-title":"Subst Abuse"},{"key":"3074_CR18","doi-asserted-by":"publisher","first-page":"209361","DOI":"10.1016\/j.josat.2024.209361","volume":"163","author":"K Jaffe","year":"2024","unstructured":"Jaffe K, et al. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults. J Subst Use Addict Treat. 2024;163:209361.","journal-title":"J Subst Use Addict Treat"},{"key":"3074_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsat.2019.08.002","volume":"106","author":"EA Evans","year":"2019","unstructured":"Evans EA, et al. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. J Subst Abuse Treat. 2019;106:19\u201328.","journal-title":"J Subst Abuse Treat"},{"key":"3074_CR20","unstructured":"Connelly LM. Trustworthiness in qualitative research. MedSurg Nurs. 2016;25(6)."},{"issue":"1","key":"3074_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1350506810386084","volume":"18","author":"G Winker","year":"2011","unstructured":"Winker G, Degele N. Intersectionality as multi-level analysis: Dealing with social inequality. Eur J women\u2019s Stud. 2011;18(1):51\u201366.","journal-title":"Eur J women\u2019s Stud"},{"issue":"3","key":"3074_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/17439760.2016.1262613","volume":"12","author":"V Clarke","year":"2017","unstructured":"Clarke V, Braun V. Thematic analysis. J Posit Psychol. 2017;12(3):297\u20138.","journal-title":"J Posit Psychol"},{"issue":"7","key":"3074_CR23","doi-asserted-by":"publisher","first-page":"e2520661","DOI":"10.1001\/jamanetworkopen.2025.20661","volume":"8","author":"E Coupet Jr","year":"2025","unstructured":"Coupet E Jr., et al. Racial and Ethnic Factors and Opioid Use Disorder Treatment After an Emergency Department Visit. JAMA Netw Open. 2025;8(7):e2520661.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3074_CR24","first-page":"qxad018","volume":"1","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, et al. Recent modifications to the US methadone treatment system are a Band-Aid-not a solution-to the nation\u2019s broken opioid use disorder treatment system. Health Aff Sch. 2023;1(1):qxad018.","journal-title":"Health Aff Sch"},{"issue":"5","key":"3074_CR25","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1097\/ADM.0000000000000973","volume":"16","author":"J Jaiswal","year":"2022","unstructured":"Jaiswal J, et al. Logistical Facilitators and Barriers to PrEP Implementation in Methadone Clinic Settings: Provider and Staff Perspectives. J Addict Med. 2022;16(5):e278\u201383.","journal-title":"J Addict Med"},{"key":"3074_CR26","volume-title":"Institute of Medicine (US) Committee on Federal Regulation ofMethadone Treatment; Federal Regulation of Methadone Treatment","author":"R Rettig","year":"1995","unstructured":"Rettig R, Yarmolinsky A. Institute of Medicine (US) Committee on Federal Regulation ofMethadone Treatment; Federal Regulation of Methadone Treatment. Washington (DC): NationalAcademiesPress (US); 1995."},{"issue":"1","key":"3074_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/00952990.2023.2291748","volume":"50","author":"JD Scheidell","year":"2024","unstructured":"Scheidell JD, Pitre M, Andraka-Christou B. Racial and ethnic inequities in substance use treatment among women with opioid use disorder. Am J Drug Alcohol Abuse. 2024;50(1):106\u201316.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"3074_CR28","first-page":"363","volume":"29","author":"S Ramanadhan","year":"2018","unstructured":"Ramanadhan S, et al. Participatory implementation science to increase the impact of evidence-based cancer prevention and control. Cancer Causes Control. 2018;29(3):363\u20139.","journal-title":"Cancer Causes Control"},{"key":"3074_CR29","doi-asserted-by":"publisher","first-page":"108721","DOI":"10.1016\/j.jsat.2022.108721","volume":"138","author":"MS Anvari","year":"2022","unstructured":"Anvari MS, et al. In their mind, they always felt less than: The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention. J Subst Abuse Treat. 2022;138:108721.","journal-title":"J Subst Abuse Treat"},{"key":"3074_CR30","doi-asserted-by":"publisher","first-page":"104511","DOI":"10.1016\/j.drugpo.2024.104511","volume":"130","author":"MB Kleinman","year":"2024","unstructured":"Kleinman MB, et al. Reduction in substance use stigma following a peer-recovery specialist behavioral activation intervention. Int J Drug Policy. 2024;130:104511.","journal-title":"Int J Drug Policy"},{"key":"3074_CR31","unstructured":"Gaffney A, Himmelstein DU, Woolhandler S. Projected Effects of Proposed Cuts in Federal Medicaid Expenditures on Medicaid Enrollment, Uninsurance, Health Care, and Health. Ann Intern Med; 2025."},{"key":"3074_CR32","unstructured":"Adams JW. The misguided reason why providers aren\u2019t prescribing more buprenorphine for opioid use disorder. 2024; Available from: https:\/\/www.statnews.com\/2024\/01\/05\/buprenorphine-prescription-x-waiver-diversion-research-opioid-use [cited 2025 August 21st]."},{"key":"3074_CR33","doi-asserted-by":"crossref","unstructured":"Perez M et al. Words matter: Stigmatizing language in medical records of individuals electing medication for opioid use disorder. Drug Alcohol Depend. 2025;275.","DOI":"10.1016\/j.drugalcdep.2025.112831"},{"issue":"1","key":"3074_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12954-023-00888-6","volume":"20","author":"JW Adams","year":"2023","unstructured":"Adams JW, et al. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study. Harm Reduct J. 2023;20(1):150.","journal-title":"Harm Reduct J"},{"key":"3074_CR35","unstructured":"Uninsurance C. .t.C.o. Coverage matters: Insurance and health care. Volume 1. National Academies; 2001."}],"container-title":["Journal of Racial and Ethnic Health Disparities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-026-03074-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40615-026-03074-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-026-03074-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:42:28Z","timestamp":1783089748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40615-026-03074-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":35,"alternative-id":["3074"],"URL":"https:\/\/doi.org\/10.1007\/s40615-026-03074-z","relation":{},"ISSN":["2197-3792","2196-8837"],"issn-type":[{"value":"2197-3792","type":"print"},{"value":"2196-8837","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}